Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice - Wikidata - awgldk - TriplyDB

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

http://www.wikidata.org/entity/Q29614979

about

Trazodone for the treatment of fibromyalgia: an open-label, 12-week study Treatment of recurrent depression Psychological therapies for treatment-resistant depression in adults Pharmacological interventions for treatment-resistant depression in adults Mirtazapine versus other antidepressive agents for depression Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose Rapid antidepressant effects: moving right along A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder Psychomotor retardation in depression: biological underpinnings, measurement, and treatment Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients The molecular neurobiology of depression A genomewide association study of citalopram response in major depressive disorder Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice Pharmacological approaches to the challenge of treatment-resistant depression Glia in the cytokine-mediated onset of depression: fine tuning the immune response Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis Ketamine, sleep, and depression: current status and new questions Neurogenetics of depression: a focus on reward processing and stress sensitivity Neuromodulation for treatment-refractory major depressive disorder Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence Cognitive mechanisms of treatment in depression Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date Ketamine for treatment-resistant unipolar depression: current evidence Pharmacotherapy of postpartum depression: an update Cell atrophy and loss in depression: reversal by antidepressant treatment A model for streamlining psychotherapy in the RDoC era: the example of 'Engage'

P2860

Q21257175-C2F24953-812B-4968-8E1B-7D9F2B192D12 Q22305946-10A64CB6-374B-4E55-A835-B2E0BAB838CF Q24202603-1C73D284-2726-42A1-B3B4-254B02E77B4D Q24202611-5D167285-3E36-4DE9-9D37-23C4A4FD807D Q24234046-A7D01D12-B38B-4D0F-95CF-39960E04ECCB Q24288801-E071FD19-D1F4-43E5-97F6-770715B631B3 Q24546379-5DC41807-13A0-4921-9BEF-779BCF758510 Q24594131-0918C64C-8E99-4F9D-9E31-37F7B790B8C2 Q24602982-DCA0A227-AF20-44B9-BDA5-C5C7152B2F78 Q24602988-50F9632F-3BF0-4652-8760-2D0F0A7D9E44 Q24606269-09514065-6216-47E4-8F0F-D63B3564F380 Q24614410-D89BF59B-CDD4-4F1B-92A9-35A1A7812464 Q24624059-D8CBA0EF-B400-46EF-A8C4-4005968D1140 Q24629825-7B6C1460-F106-425C-8E9C-16D0DB2BED43 Q24632901-50CEEE60-7714-4432-A265-1A573E7850FA Q24632936-87821870-8A3D-4528-A7A7-4E5041890956 Q24650926-5D5CF962-26D8-448E-8E63-4C57546D60B9 Q24656261-629722F5-57A3-45DC-A94B-8E7F6B39FBA9 Q24656746-73A5052C-3AD2-49E2-8EB4-F2DEAC416398 Q26747727-08DA14B1-A0B2-4685-B304-D68B855F2E81 Q26781639-C8A84A75-AC73-43AD-9D97-EAC69CC193D3 Q26782997-BCE7E2AC-3244-4AEC-8B61-1D07F84AD610 Q26796436-2D1B95A0-391C-4623-8103-29CC0B39E13F Q26797416-C29DDF59-4F3A-4970-ABDA-64DEC346AD2C Q26798241-8AB6A448-230D-48A6-A668-E386BBEB797B Q26798929-E1D8F75A-49D7-49A4-8A50-1B1D6C64222E Q26827833-2B65CDED-F620-47DA-8BE1-ADCE396B95B7 Q26828452-8981E422-7185-487B-9415-8115809710C1 Q26828564-9B3DDC04-2881-4C98-B056-BF87311CEB48 Q26830563-1CA25419-EDA2-402C-8A28-61CFA710261D Q26859023-3B2BE821-0103-479C-9D19-85904315E1DF Q26864503-C9A62467-1F8A-4AB1-8D86-82A8B680ADD3 Q26996411-C884270D-0792-40E0-B82E-9487BD8903D8 Q26999061-7569600C-5A7B-43AF-AC4A-FBEFAC699333 Q27001088-DD12CD35-4345-4CE6-B8CE-854A277D5D26 Q27004490-EFB28369-3B6F-42DF-90A0-3087877BCB6E Q27004508-CC95BD19-8BCD-4AFC-A0FB-8E958F57A1C8 Q27010062-8CEEAD0F-4C29-4244-B065-9580E6A5CC92 Q27013609-86C468F4-A187-4B53-A971-DC5CC7F96F08 Q27022793-740DEFB2-0AD8-4204-A2A7-94BC17B8FDAE

P2860

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

http://www.wikidata.org/entity/Q29614979

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Evaluation of outcomes with ci ...... ications for clinical practice

@ast

Evaluation of outcomes with ci ...... ications for clinical practice

@en

type

label

Evaluation of outcomes with ci ...... ications for clinical practice

@ast

Evaluation of outcomes with ci ...... ications for clinical practice

@en

prefLabel

Evaluation of outcomes with ci ...... ications for clinical practice

@ast

Evaluation of outcomes with ci ...... ications for clinical practice

@en

P1433

Q29614979-90CBDD9F-0DDE-409D-92DB-E6F8DB1718EF

P1476

Q29614979-5619FB48-AC35-4D61-965D-BC6C09C3AC28

P2093

Q29614979-1FE073C6-A9B8-4D0B-B2F0-2192DF09CE65

Q29614979-27CCA94C-15B2-41D0-BD6E-5475126EFFCB

Q29614979-29DCC206-7B02-415B-BC33-47B3C0EBFE3C

Q29614979-38D55658-642A-4146-BD21-C1281B524579

Q29614979-48E7624B-6CBF-4B9B-BA1F-9DAEA1410507

Q29614979-559C3B43-37C2-42F5-8D04-0B7A9F485887

Q29614979-70A0FB93-5700-4AC0-8989-849CF4B9DAF8

Q29614979-7CEC5B62-6E3B-4DB2-A6EB-36A20763DA73

Q29614979-81415DB4-E6A8-4909-AE24-77FCBE4CAAAB

Q29614979-BB9859D5-4B14-4EA0-9D1C-86E5A03FE34C

P304

Q29614979-1648A121-16DC-4754-8855-633C0A847D03

P31

Q29614979-CB90ACC9-288E-4176-A147-D8B2CB58832F

P3181

Q29614979-AFAB337D-9166-428D-B272-F816F6482FA9

P356

Q29614979-323B8A7E-6DFF-4935-9E86-56687741520B

P407

Q29614979-1018CA33-D45E-40B2-93A4-399A081B67A4

P433

Q29614979-E1D87045-943F-4257-87FE-831AC350B7A1

P478

Q29614979-51B89738-CE65-4FDB-8A8C-1CF55639724F

P577

Q29614979-95A66373-849B-4369-8CE1-647D86769068

P5875

Q29614979-10994C63-0DE2-4154-8512-7B05E8843F99

P698

Q29614979-F79CCFD4-E6AF-454E-8BEC-C047BEBBE02B

P3181

P356

APPI.AJP.163.1.28

P1433

American Journal of Psychiatry

P1476

Evaluation of outcomes with ci ...... ications for clinical practice

@en

P2093

Balasubramani GK

http://www.w3.org/2001/XMLSchema#string

Biggs MM

http://www.w3.org/2001/XMLSchema#string

Fava M

http://www.w3.org/2001/XMLSchema#string

Howland RH

http://www.w3.org/2001/XMLSchema#string

Lebowitz B

http://www.w3.org/2001/XMLSchema#string

McGrath PJ

http://www.w3.org/2001/XMLSchema#string

Nierenberg AA

http://www.w3.org/2001/XMLSchema#string

Norquist G

http://www.w3.org/2001/XMLSchema#string

Ritz L

http://www.w3.org/2001/XMLSchema#string

Rush AJ

http://www.w3.org/2001/XMLSchema#string

P304

28-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

76777

http://www.w3.org/2001/XMLSchema#string

P356

10.1176/APPI.AJP.163.1.28

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

163

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7380304

http://www.w3.org/2001/XMLSchema#string

P698

16390886

http://www.w3.org/2001/XMLSchema#string